Valences of consumer protection in the perimeter of effectiveness associated with pharmaceutical products: comment on the decisions of the C.J.E.U. in joined cases C‑495/21, C‑496/21 and in case C-616/20
PDF (Română)

Keywords

pharmaceutical products
average consumer
presentation criterion
therapeutic functionality
curative properties

Abstract

The commentary addresses the issues of the role played by the perception of the ‘average consumer’ in the regimentation of a product in one of the categories of pharmaceutical products, through the lens of the interpretative directions retained by the C.J.E.U. in the text of the decisions pronounced in the joint cases C‑495/21, C‑496/21 and in case C-616/20, for the hypotheses in which the main mode of action of a product with potential therapeutic efficacy is not scientifically ascertained, not being accredited in based on research carried out by the manufacturer. Starting from the findings that, conceptually, that product does not correspond either to the definition of the notion of ‘medical device’ in the sense of the provisions of Directive 93/42, as amended by Directive 2007/47, nor to that of ‘medicine according to the criterion of function’, in the sense of the provisions of Directive 2001/83, as amended by Directive 2004/27, and the definition of the notion of ‘medicine according to the presentation criterion’, in the meaning retained in the text of Directive 2001/83, as amended by Directive 2004/ 27 involves reporting to the criterion of subjective perception generated to consumers, on the therapeutic functions of the product, C.J.E.U. held that the elements evoked by the referring court, such as the choices made by the manufacturer regarding the presentation of the product in question as having curative properties or being capable of mitigating pathological manifestations, the references to drug interactions and adverse reactions, as well as an exclusive distribution in pharmacies represent elements which, considered as an ensemble of aspects, „are capable of making the products concerned appear to an averagely well-informed consumer to have the properties of a pharmaceutical product”.

https://doi.org/10.24193/SUBBiur.68(2023).1.4
PDF (Română)

References

AREZZO Emanuela, „The Protection of Second Therapeutical Use Inventions in the Practice of the European Patent Office”, Rivista Orizzonti del Diritto Commerciale nr. 1/2021, pp. 181-218, online: https://ssrn.com/abstract=4031581;

CAZORLA Fabian González, „Daño moral del consumidor: Análisis sobre su concepto y delimitación en España”, Revista de Derecho Civil, vol. IX, n. 3, 2022, pp. 399-427;

COMISIA EUROPEANĂ, „Orientări privind interpretarea și aplicarea Directivei 2005/29/CE a Parlamentului European și a Consiliului privind practicile comerciale neloiale ale întreprinderilor de pe piața internă față de consumatori” (2021/C 526/01), online: https://eur-lex.europa.eu/legal-content/RO/TXT/PDF/?uri=CELEX:52021XC1229(05)&from=RO;

CRAMER Lara, Innovation pharmaceutique et distribution: un changement de paradigme. Analyse comparative des droits français, allemand et suisse, L’Harmattan, Paris, 2021;

DEBARRE Jean-Michel, Prescription de médicament hors autorisation de mise sur le marché: fondements, limites, nécessités et responsabilités, LEH Editions, Bordeaux, 2017;

DREAM Robert, José Cardoso MENEZES, Antonio R. MOREIRA, „Today’s Pharma and Biotech Projects: A Phased Approach”, 2021, online: https://ispe.org/pharmaceutical-engineering/november-december-2021/todays-pharma-and-biotech-projects-phased;

GOICOVICI Juanita , Dicționar de dreptul consumului, C.H. Beck, București, 2010;

GOICOVICI Juanita, „Consumatorul aparent și profesionistul veritabil: frontierele (volutele) noțiunii de «consumator»”, în Adriana Almășan, Ioana Vârsta, Cristina Elisabeta Zamșa (coord.), In honorem Flavius Antoniu Baias. Aparența in drept, Hamangiu, București, 2021, vol. 2, pp. 727-752;

GOICOVICI Juanita, „Elementele constitutive ale practicilor comerciale neloiale în relațiile cu consumatorii”, Studia Universitatis Babes Bolyai Iurisprudentia, vol. 61, n. 3, 2016, pp. 88-100;

GOICOVICI Juanita, „Matricea răspunderii civile extracontractuale pentru prejudiciile cauzate de produsele cu defecte de manufacturare, între testul riscuri-beneficii și testul așteptărilor legitime ale consumatorului”, Studia Universitatis Babes Bolyai Iurisprudentia, vol. 67, n. 1, 2022, pp. 106-185, online: https://doi.org/10.24193/SUBBiur.67(2022).1.2 ;

GOICOVICI Juanita, Dreptul relațiilor dintre profesioniști și consumatori, Hamangiu, București, 2022;

GUERRIAUD Mathieu, „Pharmacien responsable: une exception française au service de la sécurité du médicament”, în Mathieu Guerriaud, Clotilde Jourdain-Fortier, Isabelle Moine-Dupuis (coord.), Le droit des affaires pharmaceutiques: vers une caractérisation d’une LEX pharmaceutica?, LexisNexis, Paris, 2020, pp. 14-27;

INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE, „ICH Harmonised Tripartite Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management” (Published November 2019), online: www.ich.org/page/quality-guidelines;

JACQUEMIN Hervé, Actualités en droit de la consommation, Anthemis, Wavre, 2023;

JULIEN Jérôme, Droit de la consommation, 4e édition, L.G.D.J., Paris, 2022;

LECA Jean-Baptiste, Antoine Leca, Traité de droit pharmaceutique, 11e édition, LEH Editions, Bordeaux, 2022;

MENDOZA-CAMINADE Alexandra, Médicament et droit. Droit français et européen, Larcier, Bruxelles, 2017;

MORO VISCONTI Roberto, „The Valuation of Pharma Patents”, 2021, online: http://dx.doi.org/10.2139/ssrn.4132433, accesat în 18.04.2023;

MUSCOLO Gabriella, Giovanni Pitruzzella, Competition and Patent Law in the Pharmaceutical Sector. An International Perspective, Kluwer Law International, 2016;

NDZENGUE AMOA Sabine , Santé pour tous et problématique des brevets sur les médicaments, L’Harmattan, Paris, 2022;

NOBLOT Cyril, Droit de la consommation, L.G.D.J., Paris, 2012;

PAISANT Gilles, Droit de la consommation, Presses Universitaires de France, Paris, 2019;

PELLIER Jean-Denis, Droit de la consommation, 3e édition, Dalloz, Paris, 2021;

PICOD Nathalie, Yves PICOD, Droit de la consommation, 5e édition, Sirey, Paris, 2020;

PICOD Yves, Le droit européen de la consommation, Mare et Martin, Le Kremlin-Bicêtre, 2018;

PIEDELIÈVRE Stéphane, Droit de la consommation, 3e éd., Economica, Paris, 2020;

POYNTON Aron, „The Incentive Argument in Pharmaceutical Patent Law”, 2022, online: https://ssrn.com/abstract=4204148 or http://dx.doi.org/10.2139/ssrn.4204148, accesat în 18/04.2023;

SHORTHOSE Sally, Guide to EU Pharmaceutical Regulatory Law, 6e edition, Kluwer Law International, 2016.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.